What does Actavis get in $66bn Allergan buy?
This article was originally published in Scrip
Executive Summary
When Actavis closes its $66bn acquisition of Allergan, the generic drug specialist and growing brand-name medicine marketer will grow in international markets and strengthen or add products in certain disease areas (scripintelligence.com, 18 November 2014).